# Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)

> **NCT05893056** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 25 (estimated)

## Conditions studied

- Gastric Cancer Metastatic to Liver

## Interventions

- **PROCEDURE:** Cryoablation
- **DRUG:** Tislelizumab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT05893056
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-16
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2023-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05893056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05893056, "Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05893056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*